Trial Profile
A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined With Trametinib and Dabrafenib or Trametinib in Adult Subjects With Metastatic Cutaneous Melanoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Jun 2022
Price :
$35
*
At a glance
- Drugs Navtemadlin (Primary) ; Dabrafenib; Trametinib
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Kartos Therapeutics
- 30 May 2022 Results published in the Investigational New Drugs
- 14 Dec 2018 Status changed from active, no longer recruiting to completed.
- 10 Oct 2018 Planned End Date changed from 17 Aug 2021 to 15 Oct 2019.